RCB Introduction (What it is)
RCB is short for Residual Cancer Burden.
It is a pathology-based way to measure how much cancer remains after treatment given before surgery (neoadjuvant therapy).
RCB is most commonly used in breast cancer care after neoadjuvant chemotherapy and/or targeted therapy.
It helps clinicians describe treatment response in a more detailed way than “response” versus “no response.”
Why RCB used (Purpose / benefits)
When cancer is treated before surgery (called neoadjuvant therapy), one major clinical question is: How much cancer is still present at surgery? Some people have no invasive cancer left in the breast and lymph nodes, while others have varying amounts of remaining disease. RCB was developed to address the need for a standardized, reproducible, and more nuanced measure of residual disease.
RCB is used to:
- Summarize treatment response using pathology findings from the surgical specimen.
- Stratify risk after neoadjuvant therapy by distinguishing small amounts of residual disease from extensive residual disease.
- Support clinical decision-making about additional treatment after surgery (often called adjuvant therapy), recognizing that exact treatment choices vary by cancer type and stage.
- Improve communication between pathology, surgical oncology, medical oncology, radiation oncology, and the patient.
- Standardize endpoints in clinical trials, allowing comparisons across studies that use neoadjuvant therapy.
Importantly, RCB is not a treatment and does not “detect” cancer by itself. It is a reporting framework that helps interpret the pathologic findings after neoadjuvant therapy and surgery.
Indications (When oncology clinicians use it)
RCB is typically used in scenarios such as:
- Breast cancer treated with neoadjuvant systemic therapy (for example, chemotherapy with or without targeted therapy) followed by surgery
- Cases where clinicians want a quantified pathology-based assessment of residual disease, beyond a simple yes/no response
- Clinical trials using neoadjuvant therapy where response categories are important study outcomes
- Situations where a team needs to align on post-surgery risk level to guide discussions of additional therapies and follow-up intensity
- Multidisciplinary planning when pathology must integrate breast tumor bed findings and lymph node findings after preoperative treatment
Contraindications / when it’s NOT ideal
RCB is not always suitable or informative. Examples include:
- No neoadjuvant therapy was given (RCB is designed for post-neoadjuvant surgical specimens)
- Insufficient or fragmented pathology information, such as when the tumor bed cannot be reliably assessed
- Complex cases where the original tumor site is hard to define (for example, very diffuse disease patterns), making measurements less reliable
- Scenarios where RCB has not been validated or routinely adopted for the cancer type being treated (RCB is most established in breast cancer; use in other cancers varies by clinician and case)
- When only a limited procedure is done and key elements for calculation (tumor bed size, cellularity, lymph node assessment) are not available
- When another framework is preferred for a specific institution, study protocol, or cancer subtype (approach varies by clinician and case)
These are not “safety contraindications” like those seen with medications or radiation. They are appropriateness and interpretability limitations.
How it works (Mechanism / physiology)
RCB is a pathologic scoring system, not a drug or device, so it does not have a pharmacologic “mechanism of action.” Its “mechanism” is best understood as a clinical pathway for translating surgical pathology findings into a standardized measure of residual disease after neoadjuvant therapy.
At a high level, RCB reflects the idea that prognosis and future treatment planning may differ depending on:
- How much invasive cancer remains in the breast at the original tumor site (often referred to as the tumor bed)
- How cellular the remaining tumor is (how much of the tumor bed contains viable invasive cancer versus treatment-related changes)
- The presence/extent of in situ carcinoma (non-invasive disease, such as ductal carcinoma in situ in breast cancer)
- Lymph node involvement after treatment (whether cancer remains in lymph nodes, and to what extent)
These elements are assessed by a pathologist examining the surgical specimen after neoadjuvant therapy. They are combined into an RCB result that typically falls into categories often described as:
- RCB-0 (commonly aligned with pathologic complete response in invasive disease)
- RCB-I
- RCB-II
- RCB-III
Exact definitions and calculation details are handled by pathology protocols and validated tools used by institutions. The clinical interpretation of each category can vary by cancer subtype and overall staging context.
Onset/duration and reversibility: RCB is determined after surgery and reflects the residual disease at that time point. It does not “wear off” or reverse; it is a snapshot measurement used for prognosis and planning.
RCB Procedure overview (How it’s applied)
RCB is not a procedure performed on the body. It is a structured pathology assessment performed after neoadjuvant therapy and surgery. A typical high-level workflow looks like this:
-
Evaluation/exam
Symptoms, physical exam, and history are reviewed. Goals of therapy are discussed within a multidisciplinary team. -
Imaging/biopsy/labs
Imaging (such as mammography, ultrasound, MRI, or other modalities depending on the case) and biopsy establish diagnosis and tumor features. Laboratory tests may support treatment planning. -
Staging
Clinical staging is estimated based on tumor size, nodal status, and any evidence of spread. Staging approach varies by cancer type and stage. -
Treatment planning
The team decides whether to use neoadjuvant therapy, based on tumor biology, stage, and patient factors. -
Intervention/therapy (neoadjuvant treatment)
Systemic therapy is given before surgery. Regimens vary by clinician and case. -
Surgery
The tumor site and often lymph nodes are surgically evaluated and removed according to the surgical plan. -
Response assessment (pathology and RCB)
Pathology examines the breast and lymph node specimens. Using standardized measurements, the pathologist (or the pathology team) determines the RCB category and reports relevant details. -
Follow-up/survivorship
RCB is integrated with surgical findings, staging (often “yp” pathologic staging after neoadjuvant therapy), biomarkers, and patient priorities to plan any additional treatment and follow-up surveillance.
Types / variations
RCB is most commonly discussed as category-based results derived from a standardized calculation. Common variations in practice include:
-
RCB categories (RCB-0, RCB-I, RCB-II, RCB-III)
These group patients by increasing amounts of residual disease, from none (RCB-0) to extensive (RCB-III). Interpretation can vary by cancer subtype and stage. -
Pathologic complete response (pCR) versus RCB
pCR is often a yes/no type outcome (with definitions that can differ by protocol), while RCB provides a graded spectrum of residual disease. -
Clinical care versus clinical trial usage
In clinical trials, RCB may be emphasized for standardized endpoints. In routine care, it may be reported alongside traditional pathology elements and staging. -
Institutional protocols and reporting formats
Some centers report RCB routinely in neoadjuvant breast cancer specimens; others may report the components without labeling it as RCB, depending on local practice. -
Solid-tumor focus (most common) versus other settings
RCB is primarily established in breast oncology. Use outside breast cancer is not universal and varies by clinician and case.
Pros and cons
Pros:
- Provides a standardized, pathology-based way to describe residual disease after neoadjuvant therapy
- More granular than yes/no response measures, helping distinguish minimal from substantial residual cancer
- Helps support multidisciplinary communication and shared understanding of post-surgery findings
- Can inform risk discussions and the rationale for considering additional therapy (choices vary by clinician and case)
- Useful for clinical trial consistency, improving comparability across study populations
- Anchored in objective specimen findings, not only imaging or physical exam impressions
Cons:
- Primarily validated and routinely used in breast cancer, with variable adoption elsewhere
- Depends on specimen quality and sampling, which can affect accuracy and reproducibility
- Requires careful pathology assessment; results can be sensitive to measurement variability
- Does not replace staging; it must be interpreted alongside ypTNM stage, biomarkers, margins, and nodal findings
- May be confusing for patients because it is a post-treatment metric, not a pre-treatment stage
- Not all treatment responses are captured by tumor size alone; biology can be complex, and clinical significance varies by cancer type and stage
Aftercare & longevity
Because RCB is a reporting measure, “aftercare” relates to how the result is used in ongoing cancer care rather than recovery from RCB itself.
What happens after an RCB result is reported typically depends on:
- Cancer type and stage at diagnosis and after surgery (varies by cancer type and stage)
- Tumor biology, such as receptor status and other biomarkers, which can influence recurrence risk and treatment sensitivity
- The extent and location of residual disease, including lymph node findings
- Whether surgical goals were met, such as margin status (whether tumor is at or near the edge of the removed tissue)
- The overall treatment intensity received before surgery and how well it was tolerated
- Comorbidities (other health conditions) and functional status, which may affect therapy options and follow-up plans
- Access to and engagement with supportive care, including rehabilitation, symptom management, mental health support, and survivorship resources
- Ongoing follow-up adherence, including recommended visits, imaging when appropriate, and management of long-term treatment effects
In many care pathways, RCB contributes to discussions about whether to consider additional therapies after surgery and how closely to monitor over time. The meaning of any specific RCB category should be interpreted by clinicians within the full context of the individual pathology report and overall clinical picture.
Alternatives / comparisons
RCB is one approach among several ways to assess response after neoadjuvant therapy. Common comparisons include:
-
RCB vs pCR (pathologic complete response)
pCR is often reported as an “all-or-none” outcome (with protocol-specific definitions), while RCB provides graded response categories. RCB can be especially helpful when there is residual disease and the team wants more detail than pCR alone. -
RCB vs ypTNM staging (post-neoadjuvant pathologic stage)
ypTNM describes tumor and node status after neoadjuvant therapy using standardized staging rules. RCB is a response quantification tool that complements, but does not replace, staging. -
RCB vs imaging response (MRI/ultrasound/mammography)
Imaging can estimate response and guide surgical planning, but it may not perfectly match microscopic residual disease. RCB is based on pathologic examination, which can identify residual cancer not clearly seen on imaging. -
RCB vs other pathology response systems
Some institutions use different grading systems (for example, systems focused on tumor cellularity changes). Choice of system can depend on specialty norms, institutional protocols, and study requirements. -
RCB vs observation/active surveillance
These are not direct alternatives. RCB is used after neoadjuvant therapy and surgery, whereas observation strategies apply to select cancers and scenarios where immediate treatment may not be necessary. Applicability varies by cancer type and stage. -
RCB in standard care vs clinical trials
Trials may use RCB to categorize outcomes and evaluate new regimens. Standard care uses RCB more as a communication and planning aid, integrated with guideline-based management (which varies by clinician and case).
RCB Common questions (FAQ)
Q: Is RCB a test I will feel or a procedure I undergo?
RCB is not performed on your body. It is a way for the pathology team to summarize findings from tissue removed during surgery after neoadjuvant treatment. You may see it listed in the pathology report or discussed at a follow-up visit.
Q: Does RCB mean my cancer is gone or back?
RCB describes how much cancer remains in the surgical specimen after treatment given before surgery. A lower RCB category generally indicates less residual disease, while a higher category indicates more. It does not, by itself, diagnose recurrence or predict exactly what will happen for an individual.
Q: Is anesthesia involved in RCB?
No. RCB is calculated from pathology after surgery; anesthesia relates to the surgery itself. The type of anesthesia and surgical approach depend on the operation planned and patient-specific factors.
Q: Can RCB replace staging or my biomarker results?
RCB does not replace staging (such as ypTNM) or biomarkers (such as receptor status in breast cancer). Clinicians interpret RCB alongside the full pathology report, imaging, and clinical history. Each piece provides different information.
Q: How long does it take to get an RCB result?
RCB is typically available when the final surgical pathology report is completed. Timing depends on laboratory processing, the complexity of the specimen, and whether additional studies are needed. Your care team can explain the usual turnaround at your center.
Q: What does RCB mean for additional treatment after surgery?
RCB may be one factor used to discuss whether additional therapy could be considered after surgery, because it reflects response to neoadjuvant treatment. Decisions depend on many variables, including cancer subtype, lymph node findings, surgical margins, prior treatments, and overall health. Plans vary by clinician and case.
Q: Will RCB affect my ability to work or exercise?
RCB itself will not, because it is not a treatment. Work and activity limitations are more related to surgery recovery and any additional treatments such as radiation or systemic therapy. Your team may suggest activity adjustments based on healing and symptoms.
Q: Are there side effects or risks from RCB?
RCB does not cause side effects. Any risks you experience are from the underlying cancer, neoadjuvant therapy, surgery, and follow-up treatments—not from the RCB measurement.
Q: How much does RCB cost?
RCB is generally part of the pathology assessment of a surgical specimen, so costs are typically bundled into pathology and surgical care billing. Out-of-pocket cost range varies by insurance coverage, hospital billing practices, and whether specialized calculations or consults are used. A billing office can clarify how pathology services are charged in your setting.
Q: Does RCB apply to cancers other than breast cancer?
RCB is most commonly used and discussed in breast oncology after neoadjuvant therapy. Similar “residual disease” concepts exist in other cancers, but whether RCB itself is used depends on institutional practice and available validation. If you are not being treated for breast cancer, your team may use a different response assessment method.